UBS Adjusts Estimats on Cumberland Pharmaceuticals (CPIX); IMS Trends

June 18, 2012 11:12 AM EDT Send to a Friend
Get Alerts CPIX Hot Sheet
Price: $4.64 +1.09%

Rating Summary:
    0 Buy, 4 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 26 | Down: 32 | New: 6
Trade CPIX Now!
Join SI Premium – FREE
UBS maintains a 'Neutral' on Cumberland Pharmaceuticals (NASDAQ: CPIX) price target of $7.00 (from $8.00).

Analyst, Marc Goodman, said, "Our takeaway: Caldolor sales ramp continues to disappoint Acetadone and Kristalose remain the key growth drivers for the company. Acetadote’s April sales appear to have been impacted by a switch over to the new formulation and we continue to assume that it will grow high single digits in 2012/2013 with increased penetration of the new formulation. Separately, Caldolor’s ramp continues to disappoint and we are slowing down Caldolor’s sales trajectory in our model and lowering our 2016 sales estimate from $25M to $15M. This lowered our 2012 and 2013 EPS estimates by $0.01 and $0.06, respectively." (to $0.34 and $0.47, respectively)

For an analyst ratings summary and ratings history on Cumberland Pharmaceuticals click here. For more ratings news on Cumberland Pharmaceuticals click here.

Shares of Cumberland Pharmaceuticals closed at $6.31 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment